Andreessen Horowitz

San Francisco, CA, United States

Other Business & Investment Investment & Capital

Andreessen Horowitz is a venture capital firm based in San Francisco, California. The firm is associated with prominent individuals like Chris Dixon and Davide Ulevitch and collaborates with entities such as Pioneer Fund. They have backed various companies, including TrueMed, and have a network that includes over 360 Y Combinator alumni.

Shareable draft

Check out Andreessen Horowitz on @MedStartr Today Andreessen Horowitz is a venture capital firm based in San Francisco, California. The firm is associated with prominent individuals like Chris Dixon and Davide Ulevitch and collaborates with entities such as Pioneer Fund. They have backed various companies, including TrueMed, and have a network that includes over 360 Y Combinator alumni. #ImmunoOncology #InfectiousDiseases #Hypertension #Type2Diabetes #RareDiseases #Other #BusinessInvestmentProfessionalServices #InvestmentCapital #MedMo #MedStartrVentures

https://www.medstartr.ai/s/WaDXaFDcV_w

Get Involved in Andreessen Horowitz

How We Help

Problem Statement

a16z views healthcare as an 'inefficient and costly system,' a 'data, operations, and logistics problem,' and a 'consumer experience and engagement problem' that software and technology can fundamentally improve.

Core Technology

AI in healthcare (specialized AI models for hospitals, clinics, labs), healthtech infrastructure, digital health platforms, medical devices, computational biology, and precision medicine.

Key Differentiators

Platform model providing extensive operational support beyond capital (marketing, talent, legal, policy); stage-agnostic investing (seed to late-stage); investment team often comprises ex-founders and operators; long-term view on relationships; significant investments in AI; partnership with Eli Lilly for 'The Biotech Ecosystem Venture Fund'.

Clinical Focus

Broad spectrum from life sciences to care delivery, including novel therapeutics and diagnostics.

Target Customers

Companies seeking venture capital funding and operational support in the healthcare and biotech sectors, from seed to late-stage.

Company Info

Business Model: Venture capital firm that provides capital and extensive operational support (marketing, talent, legal, policy) to companies leveraging software and technology to modernize healthcare's financial layer, improve efficiency, and enhance consumer experience. It is a stage-agnostic investor (seed to late-stage).
Founded: 2009
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: a16z.com

Disease Areas

Immuno-Oncology Infectious Diseases Hypertension Type 2 Diabetes Rare Diseases

Technologies

Precision Medicine TechAI in HealthcareHealthtech InfrastructureDigital Health PlatformsAI-driven BiomarkersGenomicsMedical DevicesComputational BiologySoftware & Platforms

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Andreessen Horowitz?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.